Umoja Biopharma Analysis: $363M Raised
What is Umoja Biopharma?
Umoja Biopharma specializes in developing in vivo CAR T cell therapies using their proprietary VivoVec platform. This technology allows for the generation of CAR T cells directly within a patient's body, significantly reducing the time from treatment initiation to availability. The company focuses on improving cancer treatment accessibility and efficacy.
Location
1616, Seattle, Washington 98102, United States
Employees
1-10
Founded
2019
Funding Status
Series C
Product Features & Capabilities
- VivoVec platform for in vivo CAR T cell therapies
- In-house manufacturing capabilities for CAR T therapeutics
Use Cases
Generate CAR T cells directly in patients; Reduce treatment wait times from weeks to immediate availability; Manufacture CAR T therapies in-house for reliable supply; Target B-cell malignancies with UB-VV111; Develop therapies for various cancers using in vivo technology
Other Considerations
Received FDA Fast Track Designation for UB-VV111; Raised $100 million in Series C financing; Named one of 2025's Most Promising Biotech Companies by Endpoints News and Fierce Biotech
See something that needs updating? Suggest edits to this profile.